Press Releases

Date Title
Toggle Summary Kura Oncology Announces Transition of Chief Medical Officer
– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and medical affairs veteran Dr. Bridget Martell named acting Chief Medical Officer – – Dr.
Toggle Summary Kura Oncology to Present at J.P. Morgan Healthcare Conference
SAN DIEGO , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced its participation at the 38th Annual J.P. Morgan Healthcare Conference .
Toggle Summary Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
Company strengthens leadership team to support pre-commercial efforts and launch optimization SAN DIEGO , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer,
Toggle Summary Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial
– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC – – Registration-directed AIM-HN trial expected to complete enrollment in first quarter of 2021 – SAN DIEGO , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.
Toggle Summary Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
– Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma – – Enhanced activity (40% CR rate, 70% ORR) observed in AITL patients with KIR mutations, a CXCL pathway-associated biomarker – – Company to conduct a single-arm, Phase 2
Toggle Summary Kura Oncology to Participate in Piper Jaffray Healthcare Conference
SAN DIEGO , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer,
Toggle Summary Kura Oncology to Present at Stifel Healthcare Conference
SAN DIEGO , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer,
Toggle Summary Kura Oncology Announces Upcoming Presentation at ASH Annual Meeting
Data from Phase 2 trial of tipifarnib in AITL accepted for oral presentation SAN DIEGO , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced
Toggle Summary Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update
– Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial – – Data from Phase 2 trial of tipifarnib in AITL accepted for oral presentation at ASH 2019 – – Initiation of first-in-class menin-MLL inhibitor KO-539 gives
Toggle Summary Kura Oncology Appoints James Basta as Chief Legal Officer
– Former Biogen senior counsel brings more than 20 years of combined in-house and law firm experience – SAN DIEGO , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of